- Home
- APVO vs VRAX Comparison
APVO vs VRAX Comparison
Compare APVO & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- VRAX
- Stock Information
- Founded
- APVO 2016
- VRAX 2013
- Country
- APVO United States
- VRAX United Kingdom
- Employees
- APVO N/A
- VRAX N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- APVO Health Care
- VRAX Health Care
- Exchange
- APVO Nasdaq
- VRAX Nasdaq
- Market Cap
- APVO 4.1M
- VRAX 4.7M
- IPO Year
- APVO N/A
- VRAX 2022
- Fundamental
- Price
- APVO $4.95
- VRAX $0.98
- Analyst Decision
- APVO Strong Buy
- VRAX Strong Buy
- Analyst Count
- APVO 1
- VRAX 1
- Target Price
- APVO $5,920.00
- VRAX $3.00
- AVG Volume (30 Days)
- APVO 393.8K
- VRAX 64.0K
- Earning Date
- APVO 05-14-2025
- VRAX 02-05-2025
- Dividend Yield
- APVO N/A
- VRAX N/A
- EPS Growth
- APVO N/A
- VRAX N/A
- EPS
- APVO N/A
- VRAX N/A
- Revenue
- APVO N/A
- VRAX $84,872.00
- Revenue This Year
- APVO N/A
- VRAX $5,169.18
- Revenue Next Year
- APVO N/A
- VRAX $66.97
- P/E Ratio
- APVO N/A
- VRAX N/A
- Revenue Growth
- APVO N/A
- VRAX 7.03
- 52 Week Low
- APVO $4.30
- VRAX $0.82
- 52 Week High
- APVO $658.60
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- APVO 28.32
- VRAX 44.60
- Support Level
- APVO $4.30
- VRAX $0.91
- Resistance Level
- APVO $5.18
- VRAX $1.03
- Average True Range (ATR)
- APVO 1.22
- VRAX 0.08
- MACD
- APVO 0.72
- VRAX -0.00
- Stochastic Oscillator
- APVO 6.47
- VRAX 24.46
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.